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Blockade of PD‑1/PD‑L1 interactions is proving an exciting, durable therapeutic modality in a range of 
cancers whereby T cells are released from checkpoint inhibition to revive their inherent anti‑tumour 
activity. Here we have studied various ways to model ex vivo T cell function in order to compare the 
impact of the clinically utilised anti‑PD‑1 antibody, pembrolizumab (Keytruda) on the activation 
of human T cells: focussing on the release of pro‑inflammatory IFNγ and anti‑inflammatory IL‑10 
to assess functionality. Firstly, we investigated the actions of pembrolizumab in an acute model of 
T‑cell activation with either immature or mature allogeneic dendritic cells (DCs); pembrolizumab 
enhanced IFNγ and IL‑10 release from purified CD4+ T‑cells in the majority of donors with a bias 
towards pro‑inflammatory cytokine release. Next, we modelled the impact of pembrolizumab in 
settings of more chronic T‑cell activation. In a 7‑day antigen‑specific response to EBV peptides, the 
presence of pembrolizumab resulted in a relatively modest increase in both IFNγ and IL‑10 release. 
Where pembrolizumab was assessed against long‑term stimulated CD4+ cells that had up‑regulated 
the exhaustion markers TIM‑3 and PD‑1, there was a highly effective enhancement of the otherwise 
exhausted response to allogeneic DCs with respect to IFNγ production. By contrast, the restoration 
of IL‑10 production was considerably more limited. Finally, to assess a direct clinical relevance we 
investigated the consequence of PD‑1/PD‑L1 blockade in the disease setting of dissociated cells from 
lung and colon carcinomas responding to allogeneic DCs: here, pembrolizumab once more enhanced 
IFNγ production from the majority of tumour preparations whereas, again, the increase in IL‑10 
release was modest at best. In conclusion, we have shown that the contribution of PD‑1—revealed by 
using a canonical blocking antibody to interrupt its interaction with PD‑L1—to the production of an 
exemplar pro‑ and anti‑inflammatory cytokine, respectively, depends in magnitude and ratio on the 
particular stimulation setting and activation status of the target T cell. We have identified a number of 
in vitro assays with response profiles that mimic features of dissociated cell populations from primary 
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tumours thereby indicating these represent disease‑relevant functional assays for the screening 
of immune checkpoint inhibitors in current and future development. Such in vitro assays may also 
support patient stratification of those likely to respond to immuno‑oncology therapies in the wider 
population.
The blockade of inhibitory immune checkpoints has emerged as a transformative strategy to achieve durable 
anti-tumour responses in patients. Immune checkpoints contribute to the control of immune responses to pre-
vent excessive tissue damage or autoimmunity. In the tumour environment however, these checkpoints can be 
subverted to prevent the immune system generating an effective anti-tumour  response1,2. The use of ipilimumab, 
an anti-CTLA-4 blocking antibody was approved by the FDA in 2011 for the treatment of metastatic melanoma. 
This has been followed by blockers of the inhibitory PD-1/PD-L1 axis including the approvals of pembrolizumab 
(Keytruda) and nivolumab (Opdivo) in 2014. Now, checkpoint inhibition has been approved in multiple cancer 
types and numerous new agents are currently undergoing clinical trials.
However, there is variability in patient responses to PD-1 treatment depending on the cancer treated, with 
patients suffering from gastric cancer, head and neck squamous cell carcinoma and small cell lung cancer having 
an overall response-rate of 12–16% compared to those with melanoma or non-small cell lung cancer having an 
overall response rate of 26–55%3. Non-responsive patients or indeed induction of severe side effects often aris-
ing from over activation of the immune system highlight the continuing need for further therapeutic strategies. 
Understanding the cellular and molecular basis as to how checkpoint blockers work should help us to discern 
which patients may respond to these agents, reveal which agents may act most effectively in combination, and 
develop new therapeutics utilising additional mechanistic approaches for patient benefit.
Co-engagement of the T-cell receptor alongside appropriate co-stimulatory signals triggers a signalling cas-
cade culminating in key T cell effector mechanisms, including cytokine release and cytotoxic  function4. The 
careful regulation of T cell activation limits collateral damage from immune system activation; however, in the 
context of tumour immunity, inhibitory ligands and factors can be upregulated by tumour cells or other cells 
within the tumour microenvironment. Such inhibitory ligands (and mechanisms), of which PD-L1 is a key 
example, can limit the activation of T cells in this environment by delivering inhibitory signals through the PD-1 
receptor and hence suppress T cell  activation5.
Cytokines such as IFNγ and IL-10 play critical roles as humoral messengers for pro-inflammatory and anti-
inflammatory signalling. For example, IFNγ is secreted by activated T cells and NK cells to promote anti-tumour 
immunity through: enhancing antigen presentation and pro-inflammatory differentiation of macrophages; sta-
bilising Th1 lineage commitment, and; restraining regulatory T cell  induction6. Furthermore, IFNγ can exert 
anti-proliferative, anti-angiogenic and pro-apoptotic effects on tumour cells directly. The archetypal suppressive 
cytokine, IL-10, can be produced by multiple cell types including regulatory T cells, Tr1 cells and  macrophages7. 
IL-10 can suppress T-cell proliferation, T cell cytokine production, dendritic cell maturation, IgE and IgG4 
production, and reduce the release of pro-inflammatory mediators from mast cells, eosinophils and  basophils8. 
In cancer, the role of IL-10 is complex having both pro- and anti-tumoural  effects9.
We have studied the impact of checkpoint inhibition on IFNγ and IL-10 release using primary human cells 
in a range of in vitro systems to identify straightforward models that could underpin the discovery and develop-
ment of immuno-oncology therapeutics while also acting as potential predictors of individual patient responses.
Materials and methods
Generation of DC. Peripheral blood mononuclear cells (PBMC) were isolated from leukocyte cones (NHS-
BTS) using Ficoll-Paque PLUS isolation. Monocytes were further enriched from PBMC using EasySep Human 
Monocyte Isolation Kit (STEMCELL Technologies, 19359), and CD14 purity verified by flow cytometry. For 
differentiation into dendritic cells (DC), monocytes were cultured at 0.5 × 106/ml in RPMI-1640 with 10% heat-
inactivated human serum (HI-HS) and Penicillin/Streptomycin (PS) (penicillin:100 U, streptomycin: 0.1 mg/ml; 
all Sigma-Aldrich), plus human (h) IL-4 (500 U) and hGM-CSF (1000 U) (both Immunotools) for 6 days. At day 
2 cells were re-fed with hIL-4 (500 U) and h-GM-CSF (1000 U).
For generation of mature DCs (mDCs), after 6 days differentiation cells were harvested, counted and returned 
to culture at 0.5 × 106/ml in RPMI-1640 with 10% HI-HS and 1% PS plus hIL-1β (1.0 μg/ml), hIL-6 (200 ng/ml), 
hTNFα (10 ng/ml) (all Immunotools), and  hPGE2 (1.0 μg/ml, Sigma-Aldrich) for a further 2 days. For immature 
DCs (iDCs) cells remained in culture for the additional 2 days without any cytokines added. After 8 days both 
mDCs and iDCs were harvested, centrifuged at 400×g for 5 min and resuspended in 10% DMSO/90% HI-HS. 
DC’s were then stored long-term in the vapour phase of liquid nitrogen.
Co‑culture of T cells with allogeneic DCs. PBMC were isolated from leukocyte cones (NHS-BTS) using 
Ficoll-Paque PLUS isolation.  CD4+ and  CD8+ T cells were enriched (separately) from PBMC using  CD4+ T cell 
Enrichment Kit and  CD8+ T cell Enrichment Kit (STEMCELL Technologies, 19052, 19053 respectively). T cells 
were then stained with proliferation dye (ThermoFisher, 65-0842-85), washed with complete media [RPMI-1640 
with 10% heat-inactivated fetal calf serum (HI-FCS) and Penicillin/Streptomycin (PS) (penicillin:100 U, strep-
tomycin: 0.1 mg/ml; all Sigma-Aldrich)], (400×g, 5 min) for 3 washes in total. T cells were cultured with either: 
iDCs or mDCs at a ratio of 100,000 T cells: 10,000 DCs in the presence of α-PD-1 (pembrolizumab [Keytruda], 
1.0 μg/ml, UHB Pharmacy), IgG4 isotype control (1.0 μg/ml, Biolegend, 403702), α-CTLA-4 (ipilimumab, [Yer-
voy], 1.0 μg/ml, UHB Pharmacy) or IgG1 isotype control (1.0 μg/ml, Biolegend, 403502) for 4 days. After 4 days 
culture, cells were stained with viability dye APC/Cy7 (BioLegend, 423106) plus either anti-human CD4 Pe/Cy7 
(BioLegend, 300512) or anti-human CD8 FITC (BioLegend, 301006). Cells were then analysed using a cyAn 
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ADP flow cytometer (Beckman Coulter). In addition, supernatants were analysed for IFNγ and IL-10 levels by 
ELISA (R&D Systems, DY285B, DY217B respectively).
Dendritic cell phenotyping. iDCs and mDCs harvested at day 8 were analysed for phenotypic markers 
by flow cytometry. Cells were fixed using Human FoxP3 Buffer Set (BD Biosciences, 560098), and stained with 
anti-human: CD80 APC, CD86 BV510, HLA-DR AlexaFluor488, PD-L1 PE, (all BioLegend, 305220, 305431, 
307656, 329705, respectively). Cells were then analysed using a cyAn ADP flow cytometer (Beckman Coulter).
Generation of exhausted  CD4+ T cells. PBMC were isolated from leukocyte cones (NHS-BTS) using 
Ficoll-Paque PLUS isolation.  CD4+ T cells were further enriched from PBMC using  CD4+ T cell Enrichment Kit 
(STEMCELL Technologies, 19052), and CD4 purity verified by flow cytometry. Cells were then cultured in a 24 
well plate at a density of 1 × 106/ml, in RPMI-1640 with 10% heat-inactivated foetal calf serum (HI-FCS) and 1% 
PS (referred to as complete media throughout). Cells were stimulated with phytohaemagglutinin (PHA; 5.0 μg/
ml; Sigma-Aldrich) and hIL-2 (1000 U; Immunotools) for 14 days. Cultures were re-fed with hIL-2 (1000 U) 
at days 3, 5, and 8. At day 0 (unstimulated cells), and after 14 days culture, cells were harvested, centrifuged at 
400×g for 5 min and resuspended in 10% DMSO/90% HI-HS. Cells were then stored long-term in the vapour 
phase of liquid nitrogen.
Co‑culture and cytokine measurements. CD4+ T cells from day 0 (unstimulated) and day 14 (PHA 
stimulated) were labelled with e450 proliferation dye (10 µM; ThermoFisher) and cultured with either: iDCs or 
mDCs at a ratio of 100,000  CD4+ T cells: 10,000 DCs in the absence (complete media) or presence of α-PD-1 
(pembrolizumab, 1.0 μg/ml, UHB Pharmacy), IgG4 isotype control (1.0 μg/ml, Biolegend, 403702), α-CTLA-4 
(ipilimumab, 1.0 μg/ml, UHB Pharmacy), or IgG1 isotype control (1.0 μg/ml, Biolegend, 403502) for 6 days. 
After 6 days culture, supernatants were analysed for IFNγ and IL-10 levels by ELISA (R&D Systems, DY285B, 
DY217B respectively). Cells were stimulated for 4  h with either brefeldin alone (10  µg/ml; Sigma-Aldrich), 
brefeldin + phorbol 12-myristate 13-acetate (PMA; 50 ng/ml; Sigma-Aldrich) or brefeldin + PMA + ionomycin 
(750 ng/ml; Sigma-Aldrich). Cells were then washed, surface labelled with anti-human CD4 BV510 (Biolegend; 
317444), fixed and permeabilised using transcription factor staining buffer set (ThermoFisher, 00-5523-00) and 
labelled with anti-human IFNγ PE and IL-10 APC (Biolegend; 506507; 506807 respectively). Cells were then 
analysed using a Cytek flow cytometer.
T cell phenotyping. Phenotypic markers expressed by  CD4+ T cells isolated at day 0 and from day 14 were 
analysed by flow cytometry. Cells were fixed using Human FoxP3 Buffer Set (BD Biosciences, 560098), and 
stained with anti-human: CD4 BV510, LAG-3 Pe/Cy7, TIM-3 PE, TIGIT PeDazzle594, CTLA-4 BV421 (all Bio-
Legend, 317444, 369310, 345006, 372716, 369606), CD3 FITC, and PD-1 APC (both ThermoFisher, 11-00390-
42, 17-2799-42 respectively). Cells were then analysed using a cyAn ADP flow cytometer (Beckman Coulter).
EBV peptide stimulation of PBMC. PBMC were isolated from a leukocyte cone (NHS-BTS) using Ficoll-
Paque PLUS isolation. PBMC were then resuspended at 2 × 106/ml and stimulated with EBNA-1 PepTivator 
(100 ng/ml, Miltenyi Biotech, 130-093-613) in the presence of α-PD-1 (pembrolizumab, 1.0 μg/ml, UHB phar-
macy) or IgG4 isotype control (1.0 μg/ml, Biolegend 403702) for 7 days. After 7 days culture, supernatants were 
analysed for IFNγ and IL-10 levels by ELISA (R&D Systems, DY285B, DY217B respectively).
Dissociated tumour cell experiments. Lung or colon tissue (obtained with appropriate Research Ethics 
Committee approval from consented patients at Heartlands Hospital or Queen Elizabeth Hospital) was ini-
tially minced before being digested in an enzyme cocktail containing: hyaluronidase, collagenase and DNAse 
(7.5 mg/ml, 1.0 mg/ml, 40 μg/ml respectively; all Sigma-Aldrich) for 1 h 15 min at 37 °C. The cell suspension 
was then washed through a 100 μm cell strainer with complete media, and then washed twice (400×g for 5 min) 
in complete media. Dead cells were removed from the cell suspension using a dead cell removal kit (Miltenyi-
Biotec, 130-090-101). The live cell fraction was washed (400×g for 5 min) in complete media and resuspended 
at 2 × 106/ml. Frozen mDCs were rapidly thawed at 37 °C, centrifuged at 400×g for 5 min in complete media 
and resuspended at 4 × 105/ml. mDCs were cultured alongside the isolated live cell fraction at a ratio of 200,000 
live cells:20,000 mDCs in the presence of α-PD-1 (pembrolizumab, 1.0 μg/ml, UHB pharmacy) or IgG4 isotype 
control (1.0 μg/ml, Biolegend 403702) for 2 days. After 2 days culture supernatants were analysed for IFNγ and 
IL-10 levels by ELISA (R&D Systems, DY285B, DY217B, respectively).
Statistical analysis. Data are presented as mean ± SEM. A Shapiro–Wilk test was used to test normality. 
2-tailed T-test, one sample T-test, one sample Wilcoxon test and Mann–Whitney U test were used to test statisti-
cal significance. Statistical analysis was performed using GraphPad Prism (version 8), and p < 0.05 was deemed 
statistically significant.
Ethical statement. All samples were obtained with informed consent and with approval from the appro-
priate Research Ethics Committee. All research was carried out in accordance with relevant guidelines and regu-
lations. All methods were approved by the relevant institution. Human colon cancer tissue from the Queen 
Elizabeth Hospital was obtained from consented patients via the Human Biomaterials Resource Centre (HBRC) 
under ethical approval (NRES Committee North West—Haydock; Ref 15/NW/0079). Human lung carcinoma 
tissue from Heartlands Hospital under national research ethical approval (REC 17/WM/0272).
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Results
Effects of pembrolizumab on IFNγ and IL‑10 levels in co‑cultures of  CD4+ T cells and allogeneic 
dendritic cells. We initially tested the impact of pembrolizumab (Keytruda) on IFNγ and IL-10 produc-
tion from purified  CD4+ T cells cultured for four days with either immature or mature allogeneic dendritic cells 
(DCs). As anticipated, mature versus immature DCs expressed higher levels of HLA-DR, CD80, CD86 and 
PD-L1 on their cell surface (Supplementary Fig. S1 online) and evoked higher levels of IFNγ in the cell culture 
supernatant in comparison to immature dendritic cells (Fig. 1A,D). In the majority of donors, pembrolizumab 
increased the levels of IFNγ measured in the supernatant from  CD4+ T cells cultured with either immature or 
mature DCs (Fig. 1A,D). Release of IFNγ by  CD8+ T cells with DCs was also increased by the presence of pem-
brolizumab, although the magnitude of the change induced by immature DCs and pembrolizumab was smaller 
than that for  CD4+ T cells (Supplementary Fig.  S2 online). PD-1 blockade also enhanced IL-10 levels from 
cultures of  CD4+ T cells and either immature or mature DCs although not to the same extent as the increase in 
IFNγ levels (Fig. 1B,E). There was a significant increase in cytokine production (both IFNγ and IL-10), relative 
to isotype control, for  CD4+ T cells in the presence of mature or immature DCs with pembrolizumab (Fig. 1C,F). 
Under these stimulation conditions, changes in  CD4+ T cell proliferation were not clearly evident in the presence 
of immature DCs. However, there was a significant increase (relative to isotype control) in  CD4+ T cell prolifera-
tion in the presence of mature DCs and pembrolizumab (Fig. 1G). We also tested the impact of the CTLA-4-tar-
getting antibody ipilimumab (Yervoy) on cytokine levels and proliferation and by contrast with pembrolizumab 
did not detect major changes under these assay conditions (Supplementary Fig. S3 online).
Effects of pembrolizumab on IFNγ and IL‑10 levels from PBMC cultures stimulated with EBV 
peptides. We next wished to characterise the impact of PD-1 blockade in antigen-specific cells under more 
chronic conditions of stimulation. Here, PBMCs were stimulated with an EBV peptide pool for seven days and, 
again, IFNγ and IL-10 were measured in the cell culture supernatant. As expected, the levels of both IFNγ and 
IL-10 were much lower than when using allogeneic DCs as a stimulus (Fig. 2A–C). Using these stimulation 
conditions, pembrolizumab again increased levels of both IFNγ and IL-10 in the PBMC cultures, which was 
statistically significant when compared with isotype control (Fig. 2C). Overall there was a somewhat greater 
release of IFNγ when comparing individual donor responses. Thus, in this setting of ‘antigen- specific’ T cells, 
pembrolizumab again was capable of enhancing T cell responses.
Impact of pembrolizumab on IFNγ and IL‑10 levels in co‑cultures of chronically stimulated T 
cells expressing exhaustion markers with allogeneic dendritic cells. In the tumour microenviron-
ment, presumed as a result of chronic antigen exposure, T cells can show a dysfunctional or ‘exhausted’ phe-
notype. We therefore wished to assess the effect of pembrolizumab on cytokine production from cells that had 
previously been chronically activated. We first stimulated  CD4+ T cells for 14 days with PHA, which increased 
the percentage (Fig. 3A,B) and MFI (Fig. 3C) of cells expressing PD-1, LAG-3, CTLA-4 and TIM-3; the number 
of TIGIT positive cells were not changed substantially in this model (Fig. 3A–C).
On subsequent stimulation of these cells, with either immature or mature allogeneic DCs, the release of IFNγ 
and IL-10 was greatly diminished when compared with cells that had not undergone prior PHA stimulation (i.e. 
unstimulated, Fig. 4). Treatment of these chronically activated ‘exhausted’  CD4+ T cells with pembrolizumab 
enhanced substantively the IFNγ response of these cells when stimulated with allogeneic DCs (Fig. 4A,D). In 
the case of immature DCs, this enhancement of IFNγ levels was greater than was evident with the unstimulated 
 CD4+ T cells. Whilst pembrolizumab also enhanced IL-10 levels in response to either immature or mature 
allogeneic DCs (Fig. 4B,E), the magnitude of this increase was considerably less than that seen for IFNγ release 
(Fig. 4C,F). For both immature and mature DCs, pembrolizumab induced a statistically significant increase in 
cytokine production (both IFNγ and IL-10) relative to isotype control (Fig. 4C,F). Therefore in this context, 
pembrolizumab skewed the cytokine response towards pro-inflammatory IFNγ over anti-inflammatory IL-10. 
Although the fold-increase was reduced compared to IFNγ, there was a trend for pembrolizumab to also enhance 
proliferation of these cells (Fig. 4G). In addition, to directly investigate the impact of pembrolizumab on IFNg 
and IL-10 production, we performed intracellular cytokine staining after re-stimulation with DCs. This revealed 
a trend towards pembrolizumab-enhancement of IFNg and IL-10 production (Supplementary Fig. S5 online).
Effects of pembrolizumab on IFNγ and IL‑10 levels in cultures of dissociated cells from solid 
tumours. To understand the impact of pembrolizumab in a clinical context, we cultured dissociated cells 
from solid tumours (either lung or colon tumours) with allogeneic DCs. Notably, pembrolizumab increased 
IFNγ levels in cultures from 9/11 lung carcinomas and 2/4 colon cancers (Fig. 5). The increase in IFNγ secretion 
from lung carcinomas elicited by pembrolizumab was statistically significant relative to isotype control (Fig. 5C). 
IL-10 levels by contrast were either not evidently affected or increased modestly only. In this context, as for the 
chronically activated T cells above, pembrolizumab skewed the cytokine response in favour of IFNγ over IL-10 
(Fig. 6).
Interestingly, from the pathologist’s report, one of the lung tumours had a PD-L1 score of 55% (i.e. 55% of 
tumour cells demonstrated positive immunoreactivity for PD-L1 determined by immunohistochemistry) and 
the dissociated cells from this carcinoma demonstrated a particularly robust response (increased secretion of 
IFNγ and IL-10) to anti-PD-1 treatment in the presence of mature DCs (Supplementary Fig. S4 online) relative 
to isotype control. In contrast, such a response was not apparent in a separate lung carcinoma that displayed 
a PD-L1 score of < 1%. This supports a potential link between PD-L1 expression by lung carcinomas and the 
ability of dissociated cells to respond to PD-1 treatment although a greater number of cases would need to be 
evaluated to allow a confident conclusion.
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Figure 1.  Pembrolizumab increases IFNγ and IL-10 levels in co-cultures of  CD4+ T cells and allogeneic 
dendritic cells. Ability of pembrolizumab (anti-PD-1; 1.0 μg/ml) to modify IFNγ (A,D) or IL-10 (B,E) levels in 
co-cultures of  CD4+ T cells and allogeneic immature (A–C) or mature (D–F) dendritic cells relative to isotype 
control. (A,B,D,E) indicate responses of individual donors (each colour represents an individual donor), (C,F) 
show percentage change in response in the presence of pembrolizumab relative to isotype control (mean + SEM, 
n = 8). (G) Shows impact of pembrolizumab upon  CD4+ T cell proliferation in the presence of allogeneic 
immature or mature dendritic cells. Data presented as percentage change relative to isotype (mean + SEM, n = 8). 
The impact of pembrolizumab was statistically significant compared to isotype control (* one sample T-test or ^ 
one sample Wilcoxon test). There was a significant difference between IFNγ and IL-10 (+ 2-tailed T-test).
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Discussion
Activation of T cells leads to the upregulation of inhibitory receptors including PD-1 and CTLA-410,11. Chronic T 
cell activation, that may occur following repeated exposure to antigens in persistent infections or cancer, is also 
associated with increased expression of inhibitory receptors such as PD-1 and CTLA-4 as well as others but leads 
to a state of T cell dysfunction whereby productive T cell responses are  compromised12,13. Canonical signalling 
via engagement with PD-1 renders the T cell receptor much less sensitive and inactivates CD28  signalling14. We 
have devised a number of in vitro models using human primary cells to study the functional impact of block-
ing PD-1 interactions with the clinically validated immuno-oncology therapeutic pembrolizumab (Keytruda). 
In all of the systems tested in this study, PD-1 blockade enhanced IFNγ production: albeit to varying degrees. 
This highlights the ability of PD-1 to impact both a polyclonal T cell population in the case of the allogeneic 
dendritic cell stimulation, and the response of chronically activated T cells to a recall antigen in the case of EBV 
peptide stimulation.
Consistent with the findings of others, pembrolizumab enhanced the increase in IFNγ levels-evoked by 
culture of allogeneic T cells with either immature or mature DCs across multiple  donors15. Under these stimula-
tion conditions, ipilimumab (Yervoy) did not enhance T cell proliferation or cytokine release. This may require 
titration of the dendritic cell/T cell ratio or may point to another mechanism of ipilimumab function within the 
tumour microenvironment, such as regulatory T cell depletion or other Fc-mediated  mechanism16–18.
Following prolonged activation of T cells, there was an upregulation of PD-1, TIM-3 and CTLA-4, markers 
associated with T cell exhaustion, although a large elevation was not evident for all exhaustion markers studied 
(LAG-3 and TIGIT). Expression of LAG-3 demarked a population of cells that were predominantly positive for 
PD-1 and TIM-3. LAG-3 is an emerging checkpoint target for cancer immunotherapy and further testing the 
responses of this subpopulation of cells is a focus of our future  studies19. Even without a complete complement of 
deemed exhaustion markers, culturing these chronically activated T cells with allogeneic dendritic cells greatly 
reduced IFNγ levels when compared to the response of non-stimulated (control) T cells. Strikingly, pembroli-
zumab was able to restore (mature DCs) or surpass (immature DCs) the IFNγ response of these chronically 
activated T cells. Again, despite the increase in CTLA-4 expression, under these conditions an impact of ipili-
mumab was not evident, which may be for the reasons discussed above. Although IL-10 levels were increased in 
the presence of pembrolizumab, they did not surpass those of control cells, suggesting that the response may be 
skewed towards a pro-inflammatory function. However, the role of IL-10 in anti-tumour immunity is complex 
with both tumour promoting and inhibiting actions  demonstrated9. Still, the functional impact of IFNγ and IL-10 
remain intriguingly linked as the anti-tumour functions of IL-10 appear dependent on IFNγ20. A considera-
tion of this assay system is the potential presence of regulatory  CD4+ T cells within the T cell population. These 
experiments were performed with the total  CD4+ T cell population as we felt this better reflected the  CD4+ T 
cell populations within the tumour and so potentially lead to a more predictive response. Mechanistic dissection 
of responses could be assisted by purification of subpopulations although an inhibition of PD-1 on regulatory 
T cells might be predicted to increase their suppressive function, which was not evident in this study, suggest-
ing the majority of the response may be contributed by conventional  CD4+ T  cells21. Moreover, the activity of 
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Figure 2.  Pembrolizumab increases IFNγ and IL-10 levels in cultures of PBMCs stimulated with EBV peptides. 
Ability of pembrolizumab (anti-PD-1; 1.0 μg/ml) to modify IFNγ (A) or IL-10 (B) levels in cultures of PBMCs 
stimulated with EBV peptides. (A,B) indicate responses of individual donors (each colour represents an 
individual donor). (C) indicates percentage change in response in the presence of pembrolizumab relative to 
isotype control (mean + SEM, n = 12). The impact of pembrolizumab was statistically significant compared to 
isotype control (*one sample T-test).
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to immune checkpoint  blockade22,23. Indeed, disrupting the synthesis of interferons by tumours enhances the 
immune checkpoint blockade  response22,23.
Pembrolizumab also enhanced intracellular expression of IFNγ and IL-10 by T cells following short-term 
stimulation with brefeldin ± PMA/ionomycin. It may be of interest in future studies to further phenotype the 
IFNγ positive cells with exhaustive cell markers (PD-1, TIM-3, LAG-3) to further investigate exhausted T cell 
sub-populations.
Although not as extensively studied as for  CD8+ T cells,  CD4+ T cells within the tumour environment do 
express markers of  exhaustion24. In mouse lymphoma and solid tumour models, blockade of PD-1 can enhance 
 CD4+ T cell-mediated anti-tumour immunity and in NSCLC patients,  CD4+ immunity was required for clinical 
responses to PD-1/PDL-1 blockade  therapy25,26.
Of all the in vitro models tested in the present study, the smallest pembrolizumab-mediated enhancement 













































































































































































































































Figure 3.  Exhausted  CD4+ T cell phenotype. Representative (n = 6) flow cytometry plots (A) demonstrating 
expression of cell surface markers (LAG-3, PD-1, TIGIT, TIM-3) indicating an exhaustive cell phenotype on 
 CD4+ T cells characterised at day 0 (unstimulated, upper panels) and after 14 days stimulated with PHA (5.0 μg/
ml, lower panels). Impact of PHA (5.0 μg/ml)-induced exhaustion upon expression of cell surface markers (PD-
1, TIM-3, LAG-3, TIGIT, CTLA-4) on  CD4+ T cells. Data presented as percentage of expressing  CD4+ T cells 
(B), and MFI of  CD4+ T cells (C), (mean + SEM, n = 4–10). The impact of PHA treatment on surface marker 
expression was significant (+ 2-tailed T-test, # Mann–Whitney U Test).
8
Vol:.(1234567890)






























































































































































































































Figure 4.  Exhausted  CD4+ T cell function. Ability of pembrolizumab (α-PD-1; 1.0 μg/ml) and ipilimumab 
(α-CTLA-4; 1.0 μg/ml) to modify IFNγ (A,D) or IL-10 (B,E) levels in co-cultures of  CD4+ T cells either 
unstimulated (clear bars) or pre-stimulated for 14 days with PHA (5.0 μg/ml; black bars) and allogeneic 
immature (A–C) or mature dendritic cells (D–F) relative to isotype control (mean + SEM, n = 9–13). (C,F) show 
percentage change in response in the presence of pembrolizumab relative to isotype control, (mean + SEM, 
n = 9–13). (G) Shows impact of pembrolizumab upon exhausted  CD4+ T cell proliferation in the presence 
of allogeneic immature or mature dendritic cells. Data presented as percentage change relative to isotype 
(mean + SEM, n = 4). There was a significant difference between PHA-treated (exhausted)  CD4+ T cells and 
unstimulated cells, and a significant difference between exhausted  CD4+ T cells treated with isotype or treated 
with pembrolizumab (# Mann–Whitney U-Test). The impact of pembrolizumab was statistically significant 
compared to isotype control (*one sample T-test or ^one sample Wilcoxon test). There was a significant 
difference between IFNγ and IL-10 (+ 2-tailed T-test, # Mann–Whitney U test).
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minimal pembrolizumab skewing towards IFNγ over IL-10. The reduced potency of this system may reflect 
lower PD-L1 levels within the culture, or a reduced sensitivity to the PD-1/PD-L1 checkpoint for regulating 
EBV-specific T cell function. CD8-positive, EBV-specific, CD28-negative IFNγ-producing T cell populations 
have been described previously, and PD-1-mediated dephosphorylation of CD28 is therefore unlikely to affect 
these  cells14,27. The presence of EBV-specific regulatory T cells, although not reported to produce IL-10, may 
further impact cytokine responses within this in vitro  system28.
Many patients treated with checkpoint inhibitors do not respond clinically and there is also a risk of side 
effects. Only two out of four colon tumours tested in the present study responded to pembrolizumab treatment. 
Possible explanations for this lack of responsiveness include a lack or insufficient number of effector T cells in 
the tumour microenvironment, an exhausted T cell phenotype that could not be reversed by pembrolizumab, or 
additional suppressive factors secreted by tumour  cells29,30. Of relevance, it is appreciated that biomarkers able to 
accurately predict patient responses would have significant clinical  value31. Indeed, the FDA has approved IHC 
assays measuring PD-1 expression, and the expression of PD-L1 seems to be associated with enhanced responses 
to anti-PD-1/PD-L1  therapy32. Nevertheless, this approach still has significant limitations in predicting patients 
that will or will not respond to these therapies. Other approaches assessing soluble biomarkers, lymphocyte sub-














































































































































Figure 5.  Response of dissociated tumour cells. Ability of pembrolizumab (anti-PD-1; 1.0 μg/ml) to modify 
IFNγ (A,D) or IL-10 (B,E) secretion by dissociated tumour cells from lung (A–C) or colon (D–F) tumours 
stimulated with allogeneic mature dendritic cells. (A,B,D,E) indicate responses of individual tumours (each 
colour represents an individual tumour), (C,F) indicate the percentage change in response in the presence 
of pembrolizumab relative to isotype control (mean + SEM; n = 11 [lung]; n = 4 [colon]). The impact of 
pembrolizumab was statistically significant compared to isotype control (^one sample Wilcoxon test). The 
difference between IFNγ and IL-10 was statistically significant (Mann–Whitney U test).
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factors such as PGE2 , IL-6 or IL-10 by patient immune cells, T cell proliferation or STAT1 signalling may also 
have prognostic value in  cancer33–37.
We found significant heterogeneity in anti-PD-1-induced increases (in terms of absolute levels or fold-changes 
in cytokines) and IFNγ/IL-10 ratios between cells from different patients or donors. In vitro assays using periph-
eral T cells or biopsy samples, such as those described in this study, could be explored for their value in predict-
ing patient responses to PD-1/PD-L1 blockade, or, for identifying new therapeutic agents synergising with this 
pathway. In support of this, defects in pathways linked to the IFNγ-signalling appear involved in development 
of resistance to PD-1 blockade and subsequent studies have shown an IFNγ-related mRNA profile that may 
predict response to PD-1  blockade38,39. Evidence that peripheral  CD8+ T cells proliferate following PD-1 therapy 
also supports the study of this accessible source of patient  cells40. Key to evaluating the predictive value of these 
types of assay is matching the in vitro responses to clinical outcomes and therefore future studies would need 
to characterise carefully defined responder and non-responder patients. At present we acknowledge that the 
absence of this information is a limitation in our study. However, having now demonstrated potentially relevant 
in vitro assays, we will focus our attention to plan studies that although clearly technically challenging, and with 
a long path to clinical validation, assess whether in vitro assays such as those described in this study may be an 
essential component of providing affordable and personalised next-generation immuno-oncology therapies to 
the wider population.
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Figure 6.  Ratio of IFNγ/IL10 responses across models. Graph showing the pembrolizumab-induced change in 
the ratio of IFNγ/IL-10 across the different in vitro models used in this study. Each point represents a donor/
patient response. Mean ± SEM, n = 8 for allogeneic iDC or mDC/ T cell, n = 12 for EBV, n = 9–13 for iDC or 
mDC / Exhausted T cell, n = 11 for lung tumour and n = 4 for colon tumour.
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